Pharmacoeconomic analysis of the treatment of schizophrenia with quetiapine, olanzapine, risperidone or haloperidol in Spain

References

• Consenso Español sobre Evaluación y Tratamiento de la Esquizofrenia. Pamplona: Sociedad Española de Psiquiatría, October 1998. Available at: http://sepsiq.org/Pub/ EvaEsq/EvaEsq-2.pdf.
   Google Scholar
• Mata I, Beperet M, Madoz V; grupo Psicost. Nuevas perspectivas en la psicopatología de los trastornos esquizofrénicos. Available at: http://www.cfnavarra.es/salud/anales/ textos/vol23/suple1/suple3a.html (accessed March 2004).
   Google Scholar
• Agustench C, Cabasés JM; grupo Psicost. Análisis y costes de servicios de la esquizofrenia en Navarra durante los tres primeros años de la enfermedad. Available at: http://www.cfnavarra.es/salud/anales/ textos/vol23/suple1/suple8a.html (accessed March 2004).
   Google Scholar
• Consenso Español de Expertos para Recomendaciones de actuación en el tratamiento de la esquizofrenia. Sociedad Española de Psiquiatría, 2000.
   Google Scholar
• Quetiapina Zeneca. Ficha técnica. Ref. QueW010.b1eMRSmPC16Aug-02. Agencia Española del Medicamento. Available at: http://www.astrazeneca.es/Article/511891. aspx.
   Google Scholar
• Nasrallah HA, Tandon R. Efficacy, safety and tolerability of quetiapine in patients with schizophrenia. Journal of Clinical Psychiatry 2002; 63(Suppl 13): 12–20.
   Google Scholar
• Base de datos de medicamentos. Consejo General de Colegios Oficiales de Farmacéuticos. Available at: http://www. portalfarma.com/home.nsf (accessed March 2004).
   Google Scholar
• Rubio-Terrés C. Introducción a la utilización de los modelos de Markov en el análisis farmacoeconómico. Farm Hosp 2000; 24: 241–247.
   Google Scholar
• Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders. ISPOR 7TH Annual International Meeting; Arlington, VA, USA; May 2002. Value in Health 2002; 5 (3): 228.
   Google Scholar
• Bagnall A-M, Jones L, Ginnelly L et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment 2003; 7: 1–193.
   Google Scholar
• Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd., 2004.
   Google Scholar
• Gilbody SM, Bagnall AM, Duggan L et al. Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd., 2004.
   Google Scholar
• Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd., 2004.
   Google Scholar
• Rummel C, Hamann J, Kissling W et al. New generation antipsychotics for first episode schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd., 2004.
   Google Scholar
• Geddes J, Freemantle N, Harrison P et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 2000; 321: 1371–1376.
   Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003; 60: 553–564.
   PubMed Web of Science ®Google Scholar
• Schulz SC, Thomson R, Brecher M. The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. Schizophrenia Research 2003; 62: 1–12.
   PubMed Web of Science ®Google Scholar
• Fabre LF, Arvanitis L, Pultz J et al. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clinical Therapeutics 1995; 17: 366–378.
   Google Scholar
• Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. Journal of Clinical Psychopharmacology 1996; 16: 158– 169.
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Seroquel (ICI 204,636): an atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study. Neuropsychopharmacology 1996; 6(Suppl 3): 171.
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Archives of General Psychiatry 1997; 54: 549–557.
   Google Scholar
• Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica 1997; 96: 265–273.
   PubMed Web of Science ®Google Scholar
• Kudo I, Nomura J, Ikawa G et al. Clinical trial of quetiapine in schizophrenia — efficacy and tolerability of quetiapine: a comparative double-blind study with mosapramine in schizophrenia patients. Annual Meeting of World Psychiatric Association; 1999 August 6–11; Hamburg, Germany.
   Google Scholar
• Murasaki M, Koyama T, Yagi MG et al. Efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia (poster). Annual Meeting of World Psychiatric Association; 1999 August 6–11; Hamburg, Germany.
   Google Scholar
• Fleischhacker WW, Linkz CGG, Hurst BC. ICI 204636 (Seroquel) — a putative new atypical antipsychotic: results from phase III trials. 8th Biennial Winter Workshop on Schizophrenia; 1996 March 16–22; Crans Montana, Switzerland.
   Google Scholar
• Emsley RA, Raniwalla J, Bailey P et al. Efficacy and tolerability of Seroquel compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment. European Neuropsychopharmacology 1996; 9(Suppl 5): S267.
   Google Scholar
• Velligan DI, Pultz J, Csernansky JG et al. Changes in cognitive function with quetiapine fumarate versus haloperidol. 152nd Annual Meeting of American Psychiatric Association; 1999 May 15–20; Washington DC, USA.
   Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clinical Therapeutics 2001; 23: 1839–1854.
   PubMed Web of Science ®Google Scholar
• San Emeterio M, Aymerich M, Faus G et al. Guía de práctica clínica para la atención al paciente con esquizofrenia. Guía de práctica clínica WGC01/2003. Agencia d‘Avaluació de Tecnología i Recerca Médiques. Barcelona, November 2003.
   Google Scholar
• Lecomte P, De Hert M, van Dijk M et al. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbation in Belgium. Value in Health 2000; 3: 1–11.
   Google Scholar
• Berengué M, Roura P. Diabetes mellitus. In: Sociedad Española de Medicina Familiar y Comunitaria. Guía de actuación en Atención Primaria. Barcelona: SemFYC, 2002: 961–970.
   Google Scholar
• Bobes J, Rejas J, García-García M et al; on behalf of the EIRE Study Group. Frequency of extrapyramidal adverse reactions in schizophrenic outpatients treated with risperidone, olanzapine, quetiapine or haloperidol. Clinical Drug Investigation 2002; 22: 609–622.
   Google Scholar
• Bobes J, García-Portilla MP, Rejas J et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. Journal of Sex & Marital Therapy 2003; 29: 125–147.
   Google Scholar
• Bobes J, Rejas J, García-García M et al; on behalf of the EIRE Study Group. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophrenia Research 2003; 62: 77–88.
   Google Scholar
• Beard SM, Lothgren M, Gudi L, Ramacciotti F, Nardini M, Berardi D. A cost-effectiveness comparison of olanzapine and risperidone in the treatment of schizophrenia in Italy. ISPOR 5TH European Congress; Rotterdamm; 2002 November 3-5; Journal of Mental Health Policy and Economics 2003; 6 (suppl. 1): S6–S7.
   Google Scholar
• Bruggeman R, Knegtering H, Castelein S et al. Risperidone versus quetiapine: preliminary results of a comparative study on sexual dysfunction and prolactin elevation. Nordic Journal of Psychiatry 2002; 56: 14.
   Google Scholar
• Crawford AM, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research 1997; 26: 41–54.
   PubMed Web of Science ®Google Scholar
• FDA Psychopharmacological Drugs Advisory Committee. Briefing Document for Zeldox capsules (Ziprasidone HCl). Food and Drug Administration, 19 July 2000.
   Google Scholar
• McIntyre RS, Trakas K, Lin D et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Canadian Journal of Psychiatry 2003; 48: 689–694. 40. Seroquel (quetiapine fumarate) tablets. Rev. SIC64154. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2003.
   Google Scholar
• Bechelli LPC, Iecco MC, Acioli A et al. A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public outpatient clinic. Current Therapeutic Research 1985; 37: 662–671.
   Google Scholar
• Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 2003; 23: 1411–1415.
   Google Scholar
• Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Medscape General Medicine 2004; 6 (1). Available at: http://www.medscape.com/ viewarticle/466800 (accessed May 2004).
   Google Scholar
• Lindenmayer JP, Czobor P, Volavka J et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry 2003; 160: 290–296.
   Google Scholar
• Cavazzoni P, Deberdt W, Kwong K et al. Pharmacoepidemiology: diabetes and antipsychotic drugs. Poster presentation at the 41st annual meeting of the New Clinical Drug Evaluation Unit; Phoenix; 2001 May 28–31.
   Google Scholar
• Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. Methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994.
   Google Scholar
• Rovira J, Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. PharmacoEconomics 1995; 8: 245–252.
   Google Scholar
• Canadian Coordinating Office for Health Technology Assessment. Guideline for economic evaluation of pharmaceuticals: Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997.
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices — modeling studies. Value in Health 2003; 6: 9–17.
   Google Scholar
• Gisbert R, Brosa M. Base de datos de costes sanitarios. Versión 1.5. Barcelona: Soikos, 2004.
   Google Scholar
• Sociedad Española de Medicina Familiar y Comunitaria. Guía de actuación en Atención Primaria. Barcelona: SemFYC, 2002.
   Google Scholar